The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study
Repository Posting Date2017-06-05T17:49:27Z
Lead Author Sigma AffliationNu Omicron-at-Large
Level of EvidenceObservational Study, Other (e.g., Prevalence, Incidence)
Keywordschemotherapy; quality of life; hematopoietic growth factor medications; Hematopoietic Cell Growth Factors; Quality of Life; Chemotherapy, Cancer; Chemotherapy, Cancer--Methods
CINAHL HeadingsHematopoietic Cell Growth Factors; Quality of Life; Chemotherapy, Cancer; Chemotherapy, Cancer--Methods
Background. Quality of life may be affected by daily injections of supportive hematopoietic growth factor medication, which is frequently required by patients with cancer undergoing chemotherapy. The objective of the study was to identify areas where long-acting derivatives of current proteins, which require less frequent administration, may provide advantages over existing therapies that require more frequent administration.
Methods. An observational study was conducted to assess the impact of daily injections of Filgrastim (Neupogen®; Amgen Inc.) on patients' quality of life. A Subject Outcome Questionnaire was administered to patients after chemotherapy on 2 consecutive cycles. Time spent for treatment and patient attitude towards injection frequency were measured. The effect on patients' daily activities, including their ability to work, was analyzed.
Results. Thirty patients completed the first, and 24 the second, administration of the Questionnaire across 3 participating sites in the United States. The average patient time commitment for each daily injection was 78 minutes. Forty-five percent of patients were moderately to extremely bothered by travel during the first chemotherapy cycle, which increased to 59% during the second cycle. Forty-four percent and 18% of patients reported having to rearrange their daily schedules and take time off from work to accommodate each injection at least some of the time, respectively. Eighty-nine percent of the patients reported a preference for a longer-acting drug that required fewer injections.
Conclusion. Results indicate that frequent injections represent a significant burden on patients' lives and that the majority would prefer longer-acting medications that require less frequent administration and potentially fewer clinic visits.
DescriptionSH and CR assisted in the design of the questionnaire. JL coordinated the study. HL and JL analyzed the data. GHL assisted in the conduct of the study and contributed to the manuscript. All authors read and approved the final manuscript.
Date of Publication2003-09-19
Citation of Original PublicationHaithcox, S., Ramnes, C. R., Lee, H., Lu, J., & Lyman, G. H. (2003). The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nursing, 2 (1). DOI: 10.1186/1472-6955-2-2. Retrieved from http://www.nursinglibrary.org/vhl/handle/10755/621408
ISSN: BMC Nursing
Version of PublicationPublisher's version
NotesThis item appears in the Virginia Henderson Global Nursing e-Repository by way of the author’s decision to publish with BMC Nursing, an open access journal, under a Creative Commons Attribution License 4.0. The license allows users to freely share and adapt the author’s material for any purpose, even commercially. Please refer to the attached license (the icon at the bottom of this entry) for further information and terms. All terms of the license have been followed. There are no changes in this article from the original posting. Neither STTI nor the Henderson Repository has any affiliation with BMC Nursing. Each shares only a mutual desire to distribute nursing research in an open access venue.
The following license files are associated with this item: